Insulin Resistance and Cancer: Why This Metabolic Problem Deserves a Central Place in Cancer Prevention

By Greg Fors, D.C., IBCN - Chief Science Consultant, Biospec Nutritionals

Nobody wants cancer in their life. And if there were a simple, practical, measurable way to improve your odds of avoiding it—or to improve the metabolic terrain that may work against recovery—would you do it?

This is the real question facing us.

For years, I have taught that insulin resistance is not just a “blood sugar problem.” It is a whole-body metabolic warning signal. It shows up as fatigue, abdominal weight gain, brain fog, post-meal crashes, rising triglycerides, stubborn inflammation, and a body that is slowly losing metabolic flexibility. Now the research is making something painfully clear: Insulin resistance is not only linked to diabetes and heart disease. It is also linked to increased risk across multiple cancers.

The new large-scale signal: insulin resistance is showing up in cancer risk

In February 2026, a Nature Communications study used a machine-learning model of insulin resistance (called AI-IR) and applied it to UK Biobank data. The researchers followed 372,395 adults who were cancer-free at baseline, and during follow-up 51,193 developed cancer. When they examined specific cancers rather than all cancers lumped together, insulin resistance was associated with significantly higher risk for multiple sites. The strongest associations were uterine cancer (HR 2.34), kidney cancer (HR 1.56), and esophageal cancer (HR 1.46). Significant associations also appeared for pancreatic cancer (HR 1.29), colon cancer (HR 1.18), and breast cancer (HR 1.14).

This matters. It means insulin resistance is not a narrow issue confined to the pancreas or the endocrine system. It appears to act like a body-wide risk amplifier. The signal showed up across several organs and was not fully explained by body weight alone. In fact, the University of Tokyo summary of the same study emphasized that BMI alone misses both false positives and false negatives: some heavier people are metabolically healthier than expected, while some normal-weight people carry significant insulin resistance and risk.

This is one of the most important take-home points for clinicians and patients alike: Body weight is not the whole story. Metabolic health is the story.

Why insulin resistance can push the body in the wrong direction

When cells become resistant to insulin, the pancreas compensates by producing more of it. That chronic hyperinsulinemia is not biologically neutral. Insulin is not only a storage hormone; it also interacts with growth signaling. Reviews published in 2024 and 2025 describe insulin resistance and hyperinsulinemia as contributors to carcinogenesis through proliferative signaling, reduced apoptosis, chronic inflammation, oxidative stress, and crosstalk with the IGF-1 axis.

In plain English, high insulin tells cells to grow. High IGF-1 signaling can reinforce that message. At the same time, chronic low-grade inflammation and oxidative stress create a terrain in which damaged cells may persist longer, divide faster, and escape normal cleanup mechanisms. This does not mean insulin resistance guarantees cancer. It does mean it can create a more favorable biological environment for cancer to develop and progress.

Why this matters years before diabetes

Another reason this topic matters is timing. Insulin resistance often shows up long before overt diabetes. In the same Nature Communications study, the insulin-resistance model predicted later diabetes and metabolic disease well before those conditions were formally diagnosed. The authors described insulin resistance as a measurable early-warning signal that could identify higher-risk individuals using ordinary clinical data.

This is exactly why I continue to emphasize fasting insulin, fasting glucose, triglycerides, HDL, waist circumference, and clinical symptoms. By the time a patient crosses the line into frank diabetes, the metabolic fire has usually been burning for years. Cancer prevention must start upstream.

Smoking, age, and “normal weight” do not erase the issue

The 2026 UK Biobank analysis also found that the insulin-resistance signal interacted with smoking history. The association with lung cancer and composite smoking-related cancers was especially notable in former smokers. The authors suggested that metabolic dysfunction and prior toxic exposures may interact in ways that further elevate risk.

This is clinically useful. Many patients think, “I quit smoking years ago,” or “I’m not that overweight,” or “My glucose is still technically normal.” But insulin resistance can still be present, still be driving inflammation, and still be amplifying risk. The absence of obesity does not prove metabolic safety.

The practical question: will people change?

Here is the hard truth: many people would rather negotiate with sugar than walk away from it.

Refined carbohydrates and simple sugars are highly rewarding, easy to overconsume, and socially normalized. But the research keeps moving in one direction: Reducing carbohydrate load improves glucose control and insulin resistance, especially in people with overweight, obesity, type 2 diabetes, and metabolic dysfunction. A 2025 meta-analysis of randomized trials found that carbohydrate-restricted diets improved fasting glucose, insulin, and HOMA-IR, with meaningful benefits appearing particularly in metabolically unhealthy groups. A separate 2025 dose-response meta-analysis likewise concluded that reducing dietary carbohydrate intake significantly improves glycemic control and insulin resistance in people with type 2 diabetes.

This does not mean every patient needs the same carb target. It does mean the standard American pattern of frequent starches, liquid sugar, snacks, desserts, and “healthy” processed carbohydrates is a disaster for the insulin-resistant patient.

Movement is not optional

Exercise remains one of the most powerful non-drug tools for improving insulin sensitivity. A 2024 systematic review focused on cancer patients found that seven of twelve included trials showed improved insulin sensitivity with physical activity, although the overall evidence base was still limited and the optimal dose remains uncertain. A 2025 NHANES analysis further found that insulin resistance significantly mediated part of the association between physical activity and lower cancer mortality.

So, the message is simple: Movement changes metabolism. It helps muscle utilize glucose, improves mitochondrial signaling, lowers insulin burden, and reduces one of the central drivers of metabolic chaos. You do not need perfection. You need consistency.

The mitochondrial connection

Insulin resistance is also a mitochondrial problem. When cells do not handle fuel properly, energy production becomes inefficient. Mitochondrial stress increases oxidative stress, worsens inflammation, and feeds the same dysfunctional terrain that underlies fatigue, metabolic syndrome, and possibly cancer biology. Recent reviews continue to describe mitochondrial dysfunction as a key part of obesity and insulin-resistance physiology, and nutrient strategies that support mitochondrial function remain a reasonable part of a broader metabolic program.

This matters because a patient with insulin resistance is often not just dealing with high glucose. They are dealing with poor fuel partitioning, reduced metabolic flexibility, oxidative stress, poor exercise tolerance, and erratic cellular energy production. This is why treatment should not stop at “eat less sugar.” We need a broader strategy that addresses insulin signaling, inflammation, lipids, and mitochondrial resilience.

Essential takeaway

If you want a cleaner metabolic terrain, one that is less favorable to diabetes, less favorable to chronic inflammation, and likely less favorable to cancer promotion, insulin resistance must move to the top of the clinical priority list. The newer research does not mean metabolic treatment replaces oncology care, but it does strongly support the following conclusion: Insulin resistance is a modifiable metabolic risk signal that deserves aggressive early attention.

This is good news, because modifiable means we can act.

Clinical action plan

1) Movement prescription

Aim for daily movement, not weekend heroics. A practical target is brisk walking after meals, resistance training two to four times per week, and a steady increase in non-exercise activity across the day. Post-meal walking is especially useful because skeletal muscle is a major site of glucose disposal. Exercise improves insulin sensitivity even when weight loss is modest.

2) Carbohydrate restriction

For many insulin-resistant adults, a reasonable starting point is to reduce total carbohydrate intake to under 200 grams per day, then titrate lower based on fasting insulin, fasting glucose, triglycerides, waist circumference, symptoms, and patient compliance. Eliminate simple sugars, sugar-sweetened beverages, fruit juice, candy, pastries, and routine dessert intake. Emphasize protein, non-starchy vegetables, healthy fats, and whole-food meals that flatten the glucose and insulin curve. Randomized-trial meta-analyses support carbohydrate restriction as a meaningful way to improve insulin resistance.

3) Stop pretending “healthy processed carbs” are harmless

For the insulin-resistant patient, excess bread, cereal, crackers, chips, sweetened yogurt, granola products, and frequent starch-based snacks still become glucose. Just because a carbohydrate is considered “complex” (as opposed to simple) does not always mean it is metabolically safe. The goal is not just to reduce table sugar. The goal is to reduce the total glycemic and insulinemic burden.

4) Consider specific nutraceutical support

Including evidence-based dietary supplements as part of a comprehensive metabolic wellness plan is an action worth exploring with a qualified healthcare professional. Supplements are not drugs, but they can add substantial value when used correctly given a patient’s individual needs and challenges. It’s also important to select supplements intelligently to avoid wasting precious time and money.

Bottom line

Cancer prevention is not reducible to one lab, one supplement, or one food. Insulin resistance is one of the clearest modifiable signals we have. It is measurable. It is common. It is often missed. And now it is showing up with increasing force in the cancer literature.

So, the question is no longer whether insulin resistance matters.

The question is whether we are willing to treat it early enough, aggressively enough, and consistently enough to change the terrain.

Biospec Nutritionals — Medical & Educational Disclaimer
This content is provided for educational and informational purposes only and is not intended to provide medical advice, diagnosis, or treatment. It is not a substitute for individualized guidance from a qualified healthcare professional. Always consult your physician or other qualified healthcare provider before starting, stopping, or changing any supplement, medication, diet, or exercise program.

† FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

References

[1] Lee CL, Yamada T, Liu WJ, et al. Machine learning-predicted insulin resistance is a risk factor for 12 types of cancer. Nature Communications. 2026.

[2] University of Tokyo. Insulin resistance predictor highlights cancer connection. February 16, 2026.

[3] Jacobo-Tovar E, et al. Insulin resistance in cancer risk and prognosis. Seminars in Cancer Biology. 2025.

[4] Szablewski L. Insulin Resistance: The Increased Risk of Cancers. Current Oncology. 2024.

[5] Fazio S, et al. Insulin resistance/hyperinsulinemia as an independent risk factor for type 2 diabetes, cardiovascular disease, cancers, cellular senescence, and frailty. 2024.

[6] Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends in Endocrinology and Metabolism. 2010.

[7] Feng S, et al. Carbohydrate-restricted diet types and macronutrient replacements for metabolic health in adults: A meta-analysis of randomized trials. Clinical Nutrition. 2025.

[8] Lan J, et al. Effect of dietary carbohydrate intake on glycaemic control and insulin resistance in type 2 diabetes: dose-response meta-analysis. 2025.

[9] Navarro-Ledesma S, et al. Physical Activity, Insulin Resistance and Cancer: A Systematic Review. Cancers. 2024.

[10] Gao K, et al. Insulin resistance mediates the association between physical activity and all-cause, cardiovascular, and cancer mortality. 2025.

[11] Zhang T, et al. The effect and mechanism of regular exercise on improving insulin resistance. 2025.

[12] Basirat A, et al. Marine-Based Omega-3 Fatty Acids and Metabolic Syndrome. 2025.

[13] Delpino FM, et al. Omega-3 supplementation and diabetes: a systematic review and meta-analysis. 2022.

[14] Mantle D, Hargreaves I. Coenzyme Q10 and Obesity: An Overview. Antioxidants. 2025.

[15] Abu-Zaid A, et al. The effect of alpha-lipoic acid supplementation on cardiometabolic risk factors: systematic review and meta-analysis. 2024.

[16] Alpha lipoic acid administration improved both peripheral and hepatic insulin sensitivity in overweight/obese patients with PCOS. 2024.